The long and growing list of potential Ozempic side effects includes but is not limited to: surgery complications, rebound weight gain, kidney injury, thyroid dysfunction, pancreatitis, hypoglycemia, and diabetic retinopathy.
We’ve known for some time that the class of drugs called GLP-1 agonists, which includes Ozempic and Zepbound, also drives thyroid cancer.
Related: Autopsy: ‘Miracle’ Weight Loss Drug Kills Fat Nurse
The gift that keeps on giving, we now have evidence that they render cancer treatments ineffective after they give it to users as well.
They get you coming and going.
Via Daily Mail (emphasis added):
Game-changing weight loss jabs relied on by millions of slimmers and diabetics could cause breast cancer treatments to stop working, experts have warned.
The drugs, which include Ozempic and Wegovy, have ushered in a new era in the battle against obesity*, helping dieters shed up to a fifth of their bodyweight.
But, American doctors tracking women being treated for an aggressive form of breast cancer have discovered the injections 'detrimentally affect' how the body responds to chemotherapy and immunotherapy.
It meant that patients on the jabs — collectively known as glucagon-like peptide-1 receptor agonists, or GLP-1s — were less likely to be totally clear of cancer after treatment and more at risk of tumours returning.
British consultant clinical oncologist Dr John Glees said the findings were 'unsettling' and added: 'These weight loss drugs are relatively new, so it's very concerning that patients taking them were less likely to be cancer free after treatment.'
In the study, hundreds of women with early-stage triple negative breast cancer were followed throughout and after treatment.
A few dozen were already taking GLP-1s and continued to do so while having cancer treatment.
Tests two years later showed just 28 per cent of women on GLP-1s responded fully to the cancer therapies, and were clear of cancer…
More than twice as many — 63 per cent — of those not on GLP-1s were cancer free**.
*The Daily Mail is — even while reporting that they drive tumor growth and prevent effective treatment thereof — seemingly contractually obligated to offer the caveat that these drugs are marvelous products of pharmaceutical innovation or whatever that every Medicaid fat needs in their medicine cabinet.
**A more than doubling in the rate of failed cancer treatments as a result of GLP-1 use is, needless to say, extremely statistically significant. In real-world application, what that means is a whole lot of people are likely going to die or suffer needlessly because they’re taking unnecessary, risky, and expensive drugs to solve a problem that, in almost all cases barring some severe underlying condition like type 1 diabetes, can be solved with lifestyle interventions.
“But wait, there’s more!” as the TV infomercial guy selling magic sponges or whatever infamously says.
A recently published non-peer-reviewed study suggests, with its findings duplicated elsewhere, that Ozempic might also trigger a rare eye disease resulting in potential vision loss.
Via Yahoo! Finance (emphasis added):
Novo Nordisk's GLP weight-loss drug Ozempic has reportedly been linked to a rare form of vision loss, known as non-arteritic anterior ischemic optic neuropathy (NAION). The study, which has yet to be peer-reviewed, was published on medRxiv and supports findings reported in a Harvard University study from this past July.
Will all of the documented possible adverse effects of GLP-1 agonists bear fruit in all cases? Probably not. But the evidence that these things are not the cure-all they’re marketed as mounts by the month.
